⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study Description

Brief Summary: This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). SECONDARY OBJECTIVES: I. To characterize the safety and tolerability of vorinostat in this patient population. II. To assess the time to tumor response (TTR). III. To assess the response duration (RD). IV. To evaluate progression free survival (PFS). V. To assess overall survival (OS). TERTIARY OBJECTIVES: I. To assess the association between a metabolic response by positron emission tomography (PET)/computed tomography (CT) after one cycle of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria (RECIST). II. To assess the association between a metabolic response by PET/CT after the first and second chemotherapy cycle and PFS. III. To assess flow sort diploid, aneuploid, and tetraploid populations of tumor cells from formalin fixed, paraffin-embedded (FFPE) tissue blocks from patients who benefited from suberoylanilide hydroxamic acid (SAHA) therapy and from patients who did not demonstrate a durable benefit. IV. Profile the genomes of each cell population using oligonucleotide comparative genomic hybridization (CGH) arrays. V. Perform whole exome analysis of the sorted tumor population and matching germ line sample for each of the patients selected. VI. To assess stable disease duration (SDD). VII. To assess the association between response to vorinostat treatment and RAD23 homolog B (HR23B) on tumor paraffin blocks. VIII. Retrospectively compare volumetric density (viable tumor volume = VTV) with pre-determined RECIST of target lesions in cross sectioning imaging (CT/magnetic resonance \[MR\]) already obtained. IX. Correlate VTV, RECIST and treatment response (partial response, stable disease, progressive disease and stable disease over 6 months). OUTLINE: Patients receive vorinostat orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up for 180 days.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States

City of Hope South Pasadena, South Pasadena, California, United States

Yale University, New Haven, Connecticut, United States

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Case Western Reserve University, Cleveland, Ohio, United States

Cleveland Veterans Administration, Cleveland, Ohio, United States

Lake University Ireland Cancer Center, Mentor, Ohio, United States

Ireland Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Contact Details

Name: Patricia LoRusso

Affiliation: Barbara Ann Karmanos Cancer Institute

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: